Related Experiment Videos

Pharmacokinetics of cefoxitin in patients with pleural effusion on a multiple dosage regimen

International Journal of Clinical Pharmacology, Therapy, and Toxicology
|June 1, 1984
PubMed

Insights

This study found that cefoxitin has a longer elimination half-life in pleural fluid (3.51 h) compared to serum (1.42 h) in patients with pleural effusion. Multiple dosing ensures therapeutic cefoxitin levels in pleural fluid.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Pleural effusion management often requires effective antibiotic penetration into the pleural space.
  • Understanding cefoxitin pharmacokinetics in pleural fluid is crucial for optimizing treatment of associated infections.

Purpose of the Study:

  • To investigate the pharmacokinetic profile of cefoxitin in serum and pleural fluid.
  • To determine the elimination half-life of cefoxitin in patients with pleural effusion.

Main Methods:

  • Pharmacokinetic study involving 6 healthy volunteers and 5 patients with pleural effusion.
  • Multiple dosage regimen of cefoxitin (30 mg/kg every 8 hours).
  • Measurement of cefoxitin concentrations in serum and pleural fluid at steady-state.

Main Results:

  • The elimination half-life of cefoxitin in pleural fluid was significantly longer (3.51 ± 1.15 h) than in serum (1.42 ± 0.51 h).
  • Steady-state concentrations were achieved in both serum and pleural fluid.

Conclusions:

  • The extended cefoxitin half-life in pleural fluid suggests sustained therapeutic concentrations.
  • The studied multiple dosage regimen is effective in maintaining adequate cefoxitin levels in pleural fluid for infection treatment.

Related Concept Videos